Landscapes / Companies
Apellis Pharmaceuticals, Inc. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
2
in active trials · 3 in all
Trials
4 active
21 since 2021
Drugs2
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Complement inhibitor |
Approved | Jul 2027Phase 3 trial completes | |||
| How it works | Blocks part of the complement system | ||||
| Next date | Jul 2027 · Phase 3 trial completes | ||||
| Also tested for | Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), Paroxysmal Nocturnal Hemoglobinuria (PNH) and 16 more | ||||
| Open drug page | |||||
— |
Phase 2 | 25 Jun 2027Phase 2 trial completes | |||
| Next date | 25 Jun 2027 · Phase 2 trial completes | ||||
| Also tested for | Geographic Atrophy Secondary to Age-related Macular Degeneration | ||||
| Open drug page | |||||
About
- No active trial
- APL-9
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021